行情

CBAY

CBAY

CymaBay
NASDAQ

实时行情|Nasdaq Last Sale

3.150
+0.080
+2.61%
盘后: 3.150 0 0.00% 17:04 01/14 EST
开盘
3.040
昨收
3.070
最高
3.165
最低
3.022
成交量
28.06万
成交额
--
52周最高
6.73
52周最低
3.022
市值
2.67亿
市盈率(TTM)
-2.7429
分时
5日
1月
3月
1年
5年
CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade
CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks · 5天前
Lvm Capital Management Ltd Buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Sells AT&T Inc, ...
Investment company Lvm Capital Management Ltd (Current Portfolio) buys Medtronic PLC, Zoetis Inc, Eaton Corp PLC, Norfolk Southern Corp, Qualcomm Inc, sells AT&T Inc, Activision Blizzard Inc, SPDR Gold Shares ETF, Conagra Brands Inc, Twilio Inc during the ...
GuruFocus.com · 01/04 18:38
10 Micro-Cap Stocks to Buy According to Hedge Funds
In this article, we will discuss 10 micro-cap stocks to buy according to hedge funds. You can skip our detailed discussion on investing in micro-cap stocks and go directly to 5 Micro-Cap Stocks to Buy According to Hedge Funds. According to historical data,...
Insider Monkey · 2021/12/16 14:14
BRIEF-TCG Crossover Management LLC Reports 7% Passive Stake In Cymabay Therapeutics
reuters.com · 2021/11/29 18:07
CymaBay Therapeutics Granted U.S. Patent #11,179,359 'Treatment of NAFLD and NASH'
View patent here
Benzinga · 2021/11/23 12:25
CymaBay Therapeutics prices ~$75M offering
CymaBay Therapeutics (NASDAQ:CBAY) has priced its previously announced public offering of common stock and pre-funded warrants. The firm is offering 15,625,000 shares of common stock and pre-funded warrants to purchase
Seekingalpha · 2021/11/18 13:31
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 2021/11/18 12:52
BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock, Pre-Funded Warrants
reuters.com · 2021/11/17 23:29
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CBAY最新的财务预测,通过CBAY每股收益,每股净资产,每股现金流等数据分析CymaBay近期的经营情况,然后做出明智的投资选择。
分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

30.00%强力推荐
70.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CBAY价格均价为11.10,最高价位14.00,最低价为7.00。
最高14.00
均价11.10
最低7.00
现价3.150
EPS
实际EPS
预期EPS
-0.27-0.20-0.14-0.07
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 189
机构持股: 5,973.21万
持股比例: 70.55%
总股本: 8,466.90万
类型机构数股数
增持
22
248.00万
建仓
19
47.20万
减持
37
343.03万
平仓
15
474.76万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.51%
制药与医学研究
+0.11%
高管信息
Non-Executive Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer/General Counsel/Secretary
Paul Quinlan
Vice President - Finance
Daniel Menold
Other
Klara Dickinson
Other
Dennis Kim
Other
Lewis Stuart
Director
Janet Dorling
Independent Director
Caroline Loewy
Independent Director
Kurt Von Emster
Independent Director
Thomas Wiggans
暂无数据
CBAY 简况
CymaBay Therapeutics Inc是一家临床阶段的生物制药公司。该公司主营业务是为肝脏和其他慢性疾病患者开发和提供治疗方法。该公司的研发管线包括三个临床阶段的候选产品,如seladelpar、MBX-2982和CB-0406。该公司还拥有一个临床前阶段的候选产品CB-001。该公司的主要候选产品seladelpar是过氧化物酶体增殖物激活受体delta(PPARd)的一种强效选择性激动剂,PPARd是一种核受体,可直接或间接调节参与胆汁酸/甾醇合成、脂质和葡萄糖代谢、炎症的基因和纤维化。该公司的MBX-2982靶向G蛋白偶联受体119(GPR119),这是一种与已知刺激葡萄糖依赖性胰岛素分泌的生物活性脂质相互作用的受体。该公司的CB-001靶向G蛋白偶联受体120(GPR1200),一种omega-3脂肪酸的受体,如二十二碳六烯酸(DHA)。

微牛提供CymaBay Therapeutics Inc(NASDAQ-CBAY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CBAY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CBAY股票基本功能。